Related Experiment Video
Updated: Apr 28, 2026
Fast and Simplified Method for High Through-put Isolation of miRNA from Highly Purified High Density Lipoprotein
Published on: July 27, 2016
microRNAs and HDL life cycle
Alberto Canfrán-Duque1, Cristina M Ramírez1, Leigh Goedeke1
1Vascular Biology and Therapeutics Program, Yale University School of Medicine, 10 Amistad Street, Amistad Research Building, Room 337C, New Haven 06510, CT, USA Integrative Cell Signalling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, CT, USA.
Abstract:
miRNAs have emerged as important regulators of lipoprotein metabolism. Work over the past few years has demonstrated that miRNAs control the expression of most of the genes associated with high-density lipoprotein (HDL) metabolism, including the ATP transporters, ABCA1 and ABCG1, and the scavenger receptor SRB1. These findings strongly suggest that miRNAs regulate HDL biogenesis, cellular cholesterol efflux, and HDL cholesterol (HDL-C) uptake in the liver, thereby controlling all of the steps of reverse cholesterol transport. Recent work in animal models has demonstrated that manipulating miRNA levels including miR-33 can increase circulating HDL-C. Importantly, antagonizing miR-33 in vivo enhances the regression and reduces the progression of atherosclerosis. These findings support the idea of developing miRNA inhibitors for the treatment of dyslipidaemia and related cardiovascular disorders such as atherosclerosis. This review article focuses on how HDL metabolism is regulated by miRNAs and how antagonizing miRNA expression could be a potential therapy for treating cardiometabolic diseases.
Insights
MicroRNAs regulate high-density lipoprotein (HDL) metabolism and cholesterol transport. Inhibiting microRNAs, like miR-33, shows potential for treating atherosclerosis and dyslipidemia.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Research
Background:
- MicroRNAs (miRNAs) are key regulators of gene expression.
- Lipoprotein metabolism, particularly high-density lipoprotein (HDL) metabolism, is intricately controlled by various genetic factors.
- Dysregulation of HDL metabolism is linked to cardiovascular diseases, including atherosclerosis.
Purpose of the Study:
- To review the role of miRNAs in regulating HDL metabolism.
- To explore the therapeutic potential of targeting miRNAs for cardiometabolic diseases.
- To discuss how miRNA manipulation impacts reverse cholesterol transport.
Main Methods:
- Review of existing literature on miRNAs and lipoprotein metabolism.
- Analysis of studies investigating miRNA involvement in HDL biogenesis and cholesterol efflux.
- Examination of animal model data on miRNA manipulation and its effects on HDL-C levels and atherosclerosis.
Main Results:
- miRNAs control key genes in HDL metabolism, such as ABCA1, ABCG1, and SRB1.
- miRNA regulation influences HDL biogenesis, cellular cholesterol efflux, and hepatic HDL cholesterol uptake.
- In vivo studies show that antagonizing miR-33 increases HDL-C and reduces atherosclerosis progression.
Conclusions:
- miRNAs are critical regulators of the entire reverse cholesterol transport pathway.
- Targeting specific miRNAs, such as miR-33, represents a promising therapeutic strategy for dyslipidemia and atherosclerosis.
- miRNA inhibitors offer a potential new avenue for treating cardiometabolic diseases.
More Related Videos
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
01:22MicroRNAs
01:10Retrovirus Life Cycles